On 14 February 2018 and 16 February 2018, the World Trade Organization (WTO) conducted a Trade Policy Review (TPR) of Malaysia. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes… Continue Reading
The Supreme Court today delivered its ruling in the case of Oil States Energy Services, LLC v. Greene’s Energy Group, LLC, holding 7-2 that inter partes review (IPR) is constitutional and does not violate Article III nor the Seventh Amendment.… Continue Reading
On April 19, 2018, KEI filed a lawsuit against the National Institutes of Health (NIH) to block or invalidate an exclusive license of patents on a new chimeric antigen receptor T-cell (CAR T) therapy to Gilead Sciences. A copy of… Continue Reading
In a 2-1 ruling, the Court of Appeals for the Fourth Circuit has ruled that Maryland’s 2017 price-gouging law (HB 631) is unconstitutional. The law (Md. Code Ann., Health–General §§ 2-801 et seq.) had prohibited price gouging (defined as an… Continue Reading
KEI was invited to participate in the “WHO Global Dialogue on Partnerships for Sustainable Financing of Noncommunicable Disease (NCD) Prevention and Control,” which was held in Copenhagen, Denmark, April 9-11, 2018. A web page for the event is here. Overall,… Continue Reading
The World Health Organization (WHO) and the Government of Denmark have convened a Global Dialogue on Partnerships for Sustainable Financing of Noncommunicable Disease (NCD) Prevention and Control from 9 April 2018 to 11 April 2018 in Copenhagen. The conference is… Continue Reading
FOR IMMEDIATE RELEASE April 5, 2018 kim.treanor@keionline.org (202)-332-2670 Six organizations are asking Department of Health and Human Services Secretary Alex Azar to take actions to lower the price of eteplirsen, a drug sold under the brand name Exondys 51, to… Continue Reading
In March 2018, the Office of the United States Trade Representative (USTR) published its 2018 National Trade Estimate Report on Foreign Trade Barriers (NTE). Every year, the USTR is mandated to “submit to the President,the Senate Finance Committee, and appropriate… Continue Reading
KEI has submitted a request to Mr. James Carroll, Acting Director of the Office of National Drug Control Policy, and to Ms. Kellyanne Conway, Counselor to the President and appointed “opioid czar,” asking that the federal government use its authority… Continue Reading
On March 21, 2018, KEI asked the NIH to investigate the failure of James Griffin, the Dana-Farber Cancer Institute and Novartis to disclose millions of dollars in NIH grants related to two patents for the leukemia drug midostaurin, marketed by… Continue Reading